Point: If It Is Important to Prevent Type 2 Diabetes, It Is Important to Consider All Proven Therapies Within a Comprehensive Approach
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Type 2 diabetes is a common metabolic disease that is defined on the basis of glucose levels above specific thresholds. Individuals with type 2 diabetes are at high risk of blindness, renal failure, amputation, cardiovascular disease, premature death, dementia, and a variety of other chronic diseases and life-threatening events. However, unlike other risk factors for future events (e.g., hyperlipidemia or hypertension), type 2 diabetes is often associated with symptoms and discomfort related to elevated glucose levels that range from fatigue, nocturia, polyuria, and nonspecific aches and pains to dehydration and coma. Moreover, once diabetes is diagnosed, affected individuals incur additional cost and inconvenience related to disease labeling, dietary and lifestyle modification, glucose monitoring, eye assessments, and higher health and life insurance premiums. Several trials have shown that aggressive management of type 2 diabetes can reduce the risk of microvascular disease (1–3), and that multifactorial risk factor interventions can reduce the risk of these and other consequences (4–6). These considerations and epidemiologic evidence that the risk of eye and kidney disease is well below the diagnostic thresholds for diabetes suggest that if glucose levels are prevented from rising past these thresholds, or the rise is delayed, these consequences will also be prevented or delayed. Moreover, evidence that the glucose level is a progressive risk factor for cardiovascular events (i.e., that the risk rises with the glucose level) (7–11) supports the hypothesis that preventing or delaying any rise within the nondiabetic range may reduce the risk of cardiovascular events. Finally, if ongoing clinical trials (12 …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 1×
“Clinical trials in individuals with impaired glucose tolerance (IGT) have clearly shown that a program of diet and exercise can substantially reduce the incidence of type 2 diabetes by 60% (14,15), and that the glucose-lowering drugs metformin and acarbose can reduce the incidence of diabetes by 25–30% (14,16).”
BackgroundXENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915 · cited 1×
“One clinical trial (18) of a weight-reducing drug reported a 37% risk reduction in obese individuals.”
BackgroundRamachandran, A., Snehalatha, C., Mary, S., Mukesh, B., Bhaskar, A. D., Vijay, V., & Indian Diabetes Prevention Programme (IDPP) (2006) · Diabetologia · doi:10.1007/s00125-005-0097-z · Cited by 1,881
(2006) · The Lancet · doi:10.1016/s0140-6736(06)69420-8 · Cited by 1,706 · cited 4×
“However, the fact that only 43% of the randomized participants were followed for the full study period and that benefits were most apparent in the IGT subgroup make it difficult to generalize these findings to all obese individuals.”
BackgroundInfluentialChiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., Laakso, M., & for The STOP-NIDDM Trial Research Group (2003) · JAMA · doi:10.1001/jama.290.4.486 · Cited by 1,624 · cited 1×
“Such a possibility has already been raised by at least one diabetes prevention trial (13).”
BackgroundBuchanan, T. A., Xiang, A. H., Peters, R. K., Kjos, S. L., Marroquin, A., Goico, J., Ochoa, C., Tan, S., Berkowitz, K., Hodis, H. N., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.9.2796 · Cited by 1,339
Gæde, P., Vedel, P., Parving, H.-H., & Pedersen, O. (1999) · The Lancet · doi:10.1016/s0140-6736(98)07368-1 · Cited by 981
Khaw, K.-T., Wareham, N., Bingham, S., Luben, R., Welch, A., & Day, N. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-6-200409210-00006 · Cited by 974
Effect of ramipril on the incidence of diabetes
(2006) · New England Journal of Medicine · doi:10.1056/nejmoa065061 · Cited by 737
Cited by
Standards of medical care in diabetes 2010
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s011 · Cited by 3,470
Standards of medical care in diabetes—2011
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s011 · Cited by 2,880
Standards of Medical Care in Diabetes—2009
American Diabetes Association (2009) · Diabetes Care · doi:10.2337/dc09-s013 · Cited by 2,167
“This table has been reprinted with permission (30) with some”
Standards of Medical Care in Diabetes 2014
(2014) · Majmaah Journal of Health Sciences · doi:10.12816/0004790 · Cited by 1,465
Standards of Medical Care in Diabetes—2008
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-s012 · Cited by 1,377
“‡references are numbered as in original publication (25).”
Background
Metadata
- Authors
- Gerstein, H. C.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2007-02-01
- Volume
- 30
- Issue
- 2
- Pages
- 432-434
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2151948580
- Cited by
- 16
- References
- 16
- FWCI
- 2.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Point: If It Is Important to Prevent Type 2 Diabetes, It Is Important to Consider All Proven Therapies Within a Comprehensive Approach. https://app.cochat.ai/papers/10.2337/dc06-2147
- The paper
- Gerstein, H. C. (2007). Point: If It Is Important to Prevent Type 2 Diabetes, It Is Important to Consider All Proven Therapies Within a Comprehensive Approach. Diabetes Care. https://doi.org/10.2337/dc06-2147
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.